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Abstract 
Purpose: Early assessment of tumor responses to chemotherapy could enhance treatment 
outcomes by ensuring that, from the beginning, treatments meet the individualized needs of 
patients.  In  this  study,  we  applied  multiple  modality  molecular  imaging  techniques  to 
pre-clinical monitoring of early tumor responses to Doxil, focusing on imaging of apoptosis. 
Methods: Mice bearing UM-SCC-22B human head and neck squamous cancer tumors re-
ceived either PBS or 1 to 2 doses of Doxil® (doxorubicin HCl liposome injection) (10 
mg/kg/dose).  Bioluminescence  signals  from  an  apoptosis-responsive  reporter  gene  were 
captured for apoptosis evaluation. Tumor metabolism and proliferation were assessed by
 
18F-FDG and 3’-
18F-fluoro-3’-deoxythymidine (
18F-FLT) positron emission tomography. Dif-
fusion-weighted magnetic resonance imaging (DW-MRI) was performed to calculate averaged 
apparent diffusion coefficients (ADCs) for the whole tumor volume. After imaging, tumor 
samples  were  collected  for  histological  evaluation,  including  terminal  deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL), anti-CD31, and Ki-67 immunostaining.  
Results: Two doses of Doxil significantly inhibited tumor growth. Bioluminescence imaging 
(BLI) indicated apoptosis of tumor cells after just 1 dose of Doxil treatment, before apparent 
tumor shrinkage. 
18F-FDG and 
18F-FLT PET imaging identified decreased tumor metabolism 
and proliferation at later time points than those at which BLI indicated apoptosis.  MRI 
measurements of ADC altered in response to Doxil, but only after tumors were treated with 
2 doses. Decreased tumor proliferation and increased apoptotic cells were confirmed by 
changes of Ki-67 index and apoptotic ratio. 
Conclusion: Our study of tumor responses to different doses of Doxil demonstrated that it 
is essential to combine apoptosis imaging strategies with imaging of other critical biological or 
pathological pathways, such as metabolism and proliferation, to improve clinical decision 
making in apoptosis-related diseases and interventions. 
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Introduction 
It  is  well  known  that  most  chemotherapeutic 
agents cause tumor cell death primarily by induction 
of apoptosis, and resistance to anticancer treatment is 
widely believed to involve mutations that lead to de-
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regulated  cellular  proliferation  and  suppression  of 
mechanisms that enable apoptosis [1]. The anthracy-
cline antibiotic doxorubicin, originally isolated from 
the fungus Streptomyces peucetius, is a chemothera-
peutic agent with strong activity against a wide range 
of human malignant neoplasms [2]. So far, the exact 
action mechanism of doxorubicin is unknown, but is 
believed  to  be  related  to  several  pathways.  First, 
doxorubicin intercalates between adjacent DNA base 
pairs, which may prevent DNA replication and tran-
scription.  Second,  the  drug-associated  complex  fur-
ther  leads  to  inhibition  of  the  catalytic  activity  of 
topoisomerase II [3]. At higher concentrations, how-
ever, this inhibition may be reversed [4]. Third, dox-
orubicin can form free radicals, capable of damaging 
cancer  cells.  However,  the  importance  of  such  free 
radical damage in killing tumor cells by doxorubicin 
is still unclear [5].  
Apart  from  side-effects  that  are  common  to 
many  cancer  chemotherapeutics,  the  clinical  useful-
ness of doxorubicin is limited largely by a cumulative 
dose-related cardiomyopathy that manifests itself as 
congestive  heart  failure  [2].  Doxil  is  a  doxorubicin 
formulation  in  which  the  drug  is  encapsulated  in 
stealth liposomes that can avoid clearance by the re-
ticuloendothelial system [6]. As a result, Doxil has a 
long circulation time, and it selectively extravasates 
through the abnormally permeable vessels character-
istic of many tumors [7]. Human and animal studies 
demonstrate  that  Doxil  achieves  higher  concentra-
tions  than  doxorubicin  in  tumor  tissue,  relative  to 
serum concentrations [8]. 
In  this  study,  we  genetically  engineered 
UM-SCC-22B human head and neck squamous cancer 
cells with cyclic luciferase, an endogenous apoptosis 
marker.  We  applied  multiple  imaging  strategies  to 
monitor  tumor  responses  to  Doxil  in  22B  xenograft 
mice,  including  bioluminescence  imaging  (BLI)  and 
diffusion-weighted  magnetic  resonance  imaging 
(DW-MRI). In addition, we performed PET imaging 
with  18F-FDG to monitor tumor glucose metabolism 
and 18F-FLT to monitor tumor proliferation. 
Materials and Methods 
Cell line and animal model 
pcFluc-DEVD plasmid was generously provided 
by Dr. T. Ozawa (Department of Chemistry, School of 
Science, The University of Tokyo; Japan Science and 
Technology  Agency,  Tokyo,  Japan).  UM-SCC-22B 
human head and neck squamous cells were cultured 
in Dulbecco’s modified medium supplemented with 
10% (v/v) heat-inactivated FBS, 100 unit/mL penicil-
lin,  and  100  μg/mL  streptomycin  at  37°C  in  an  at-
mosphere of 5% (v/v) CO2. Cells were seeded onto 
6-well culture plates, transfected with pcFluc–DEVD 
plasmid in the presence of Lipofectamine 2000. A sin-
gle  clone  of  stably-transfected  cells,  denoted 
22B-cFluc-DEVD,  was  selected  by  the  addition  of 
G418 (Sigma) to the culture medium for two weeks.  
Six-week old female athymic mice were obtained 
from the NIH Division of Veterinary Resources and 
maintained on a standard diet at room temperature 
(RT). The animal experiments were approved by the 
Institutional Animal Care and Use Committee of the 
Clinical Center, NIH. Each nude mouse was injected 
subcutaneously with 2×106 22B-pcFluc-DEVD cells (in 
100 μL PBS) in the right  shoulder. Tumor size was 
monitored with a digital caliper and tumor volume 
was calculated as ab2/2, where a is the longest diam-
eter and b is the shortest diameter. Seven days after 
inoculation, 18 mice with a tumor volume around 150 
mm3  were  randomized  into  three  groups  (n  = 
6/group).  One  group  of  mice  received  1  dose  of 
10mg/kg of Doxil (ALZA Corporation, USA) through 
intravenous  administration.  Another  group  of  mice 
received two doses of Doxil with an interval of 2 days. 
The control group of mice received PBS only. Doses 
were selected to mimic high dose strategies used in 
clinical chemotherapy regimens. Animals underwent 
MRI, bioluminescence imaging, optical imaging and a 
PET scan at 48 hr after each Doxil or PBS administra-
tion. Animal status was monitored closely throughout 
the experiment.  
Radiotracers 
18F-FDG  was  purchased  from  the  Nuclear 
Pharmacy of Cardinal Health, and reconstituted with 
sterile saline. The average radiochemical purity of the 
product was 98.5% and specific activity  was >1,000 
Ci/mmol. Synthesis of  18F-FLT was prepared manu-
ally according to methods in previous reports [9-10]. 
For  purification  of  18F-FLT,  a  semi-preparative  C18 
HPLC  column  (Phenomenex  Nucleosil  C18  column, 
108005; 5 mm, 300 × 10 mm) was eluted with 8% eth-
anol/H2O  (4  ml/min).  Radiochemical  yields  (decay 
uncorrected) for 18F-FLT were 64.6 ± 8.3% (n = 5).  
MRI imaging 
Small animal MRI was conducted on a Bruker 
BioSpec  7.0  T  system  (Bruker  BioSpin  Corp.).  The 
animals were placed on a holding bed equipped with 
circulating warm water to regulate body temperature 
during MRI scans. While the animals were under an-
esthesia,  anatomic  images  were  acquired  using  a 
T1-weighted MRI. A T2-weighted spin echo sequence 
(RARE) was then used with the following acquisition 
parameters:  repetition  time  (TR)/echo  time  (TE), Theranostics 2011, 1 
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2,000/48.8 ms; 256 × 256 matrix; and a 30 × 30 mm 
field of view. Continuous 1 mm thick slices were used 
to cover the entire tumor region. Diffusion weighted 
imaging (DWI) data were collected using a standard 
spin echo sequence with two b-factors (5 and 1,000 
s/mm2) in three orthogonal gradient directions (x, y, 
z). The acquisition parameters were as follows: repe-
tition time (TR)/echo time (TE), 2750/90 ms; diffusion 
separation time, 16 ms; diffusion gradient duration, 6 
ms; 128 × 128 matrix; and a 30 × 30 mm field of view. 
A total of three to five 1 mm-thick slices (1 mm gap) 
were used to cover tumor regions of interest. A mag-
netic resonance–compatible small animal respiratory 
gating device (SA Instrument, Inc.) was used during 
the scans.  
Bioluminescence Imaging 
Bioluminescence imaging was acquired with an 
IVIS100 imaging system (Xenogen) after MRI on each 
imaging day. Each mouse was injected intraperitone-
ally with D-luciferin at a dose of 2.5 mg/kg in 0.1 mL. 
Five  min  later,  the  animals  were  positioned  on  a 
temperature-controlled  warm  bed  (37°C)  under 
isoflurane anesthesia (1–2%). Photons were collected 
for 180 seconds. Images were analyzed with Living 
Image v.3.1 software (Caliper Life Sciences). 
18F-FLT PET and 
18F-FDG PET imaging 
For  18F-FLT PET imaging the animals were ad-
ministered  1.85  MBq  (50  µCi)  18F-FLT  via  tail  vein 
injection. Animals remained conscious and were al-
lowed free access to food and water during a 1 h up-
take period. The mice were anesthetized (2% isoflu-
rane in O2 at 2 L/min) immediately before scanning 
and were imaged in the prone position for 10 min. 
Body temperature was maintained before and during 
imaging using a thermostatically controlled circulat-
ing warm water pad.  
Eight hours after 18F-FLT PET imaging, the same 
animals received 0.85 MBq (50 µCi)  18F-FDG via in-
travenous  injection.  They  were  maintained  under 
isoflurane anesthesia during the injection, accumula-
tion, and scanning periods. The images were recon-
structed and analyzed as reported previously [11].  
Histologic analysis 
Tumor samples were collected and sectioned af-
ter the animals were sacrificed. DNA fragmentation 
was analyzed by terminal deoxynucleotidyl transfer-
ase mediated dUTP nick end labeling (TUNEL) assay 
using a commercial kit (Maxin-Bio) according to the 
manufacturer's  protocol.  In  random  fields,  the  per-
centage of all nuclei that were TUNEL-positive nuclei 
was determined and used as the apoptotic index.  
Frozen tumor tissue slices were fixed with cold 
acetone for 20 min and dried in the air for 30 min at 
room  temperature. For  staining  of  CD31,  the  slices 
were blocked with 1% bovine serum albumin for 30 
min,  incubated with  rat  anti-mouse  CD31  antibody 
(1:200;  BD  Biosciences)  and  then  visualized  with 
Cy3-conjugated  goat  anti-rat  secondary  antibody 
(1:300;  Jackson  ImmunoResearch  Laboratories).  For 
Ki-67 staining, slices were incubated with rabbit an-
ti-mouse Ki-67 antibody (1:200; BD Biosciences), and 
then visualized with Cy3-conjugated goat anti-rabbit 
secondary antibody (1:300; Jackson ImmunoResearch 
Laboratories).  Both  types  of  stained  slices  were 
washed  3  times  with  PBS,  mounted  with 
4'-6-diamidino-2-phenylindole  (DAPI)-containing 
mounting medium, and observed under an epifluo-
rescence  microscope  (X81;  Olympus).  Each  experi-
ment was performed in pairs, and the pairs were then 
repeated twice. Image J software (NIH) was used to 
assess the total number of DAPI positive nuclei, Ki-67 
positive nuclei number, and the CD31-positive area. 
The Ki-67 staining index (SI) was defined as the per-
centage of positive nuclei within the total number of 
nuclei.  For  each  tumor  section,  ten  random  images 
were analyzed 20 times. 
Statistical Analysis  
Quantitative data were expressed as mean ± SD. 
Statistical analysis was done using an unpaired Stu-
dent’s t tests. P values less than 0.05 were considered 
statistically significant. 
Results 
Doxil treatment inhibits UM-SCC-22B tumor 
growth  
As  shown  in  Figure  1A,  a  time-dependent  in-
crease in tumor volume was observed in the control 
group. The average tumor growth rates in the control 
group, expressed as V/V0, were 1.35 ± 0.27 and 1.62 ± 
0.28 at day 3 and day 5, respectively. Meanwhile, the 
Doxil treatment group showed V/V0 ratios of 1.27 ± 
0.28 and 0.96 ± 0.27 at day 3 and day 5, respectively. 
No  significant  difference  in  tumor  volume  was  ob-
served  at  day  3  after  1  dose  of  Doxil  treatment. 
However, a significant tumor size difference between 
the treatment group and the control group was ob-
served (p < 0.01) on day 5. There was no significant 
body weight loss observed during the treatment pro-
cess.  
Doxil induces apoptosis in 22B tumors 
Reporter  genes  containing  the  caspase-3  sub-
strate  peptide  DEVD  (aspartic  acid-glutamic  ac-
id-valine-aspartic acid) have been reported to monitor 
caspase-3  activity  when  cells  undergo  apoptosis Theranostics 2011, 1 
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[12-15].  One  example  is  a  DEVD  containing  cyclic 
luciferase. With this method, two fragments of DnaE 
intein were fused to neighboring ends of firefly lucif-
erase connected with a DEVD sequence. After trans-
lation  into  a  single  polypeptide  in  living  cells,  the 
amino (N) and carboxy (C) terminals of the luciferase 
were ligated by protein splicing, which resulted in a 
closed circular polypeptide chain. When the substrate 
sequence  was  digested  by  caspases,  the  luciferase 
changed into an active form and regained its activity 
[16]. As shown in Figure 1B and C, in the PBS-treated 
control tumors, only background level of BLI signal 
was observed. After being treated with Doxil, the BLI 
signal  intensity  increased  dramatically.  The  results 
indicate increased caspase-3 activity associated with 
apoptosis. 
18F-FDG and 18F-FLT PET imaging 
PET  imaging  with  FDG  and  FLT  has  been 
well-adopted for the evaluation of tumor metabolism 
and proliferation. On the static FGD PET images in 
our  study,  UM-SCC-22B  tumors  showed  clear  con-
trast  relative  to  surrounding  tissues  (other  than  to 
brain  and  heart).  We  used  tumor-to-muscle  ratio 
(T/M) to standardize the PET quantification. At 48 hr 
after 1 dose of Doxil treatment, there was no signifi-
cant change of FDG uptake in treated versus control 
tumors (5.46 ± 0.36 vs. 4.44 ± 1.81, p > 0.05). Tumors 
that  received  2  doses  of  Doxil  showed  significantly 
lower FDG uptake than the baseline scan with a T/M 
of 2.27 ± 0.41 (p < 0.01) (Figure 2A & B). UM-SCC-22B 
tumors showed positive FLT uptake, but no signifi-
cant change after treatment with 1 dose of Doxil (p > 
0.05). After 2 doses of Doxil treatment, the T/M ratio 
dropped  from  3.32  ±  0.24  to  2.65  ±  0.13  (p  <  0.05) 
(Figure 3A & B).  
DW-MRI 
Figure  4  shows  a  representative  set  of  regular 
MR images, as well as the ADC map calculated from 
diffusion weighted images. The ADC maps revealed 
increases in ADC with increased Doxil dose. In the 
PBS control group, the average ADC value was 0.57 ± 
0.04 mm2/s. In the Doxil treatment group, one dose of 
Doxil produced little change of ADC value (0.59 ± 0.04 
mm2/s). After 2 doses of Doxil, however, the mean 
ADC value increased to 0.87 ± 0.05 mm2/s (p < 0.01). 
 
 
Figure 1. (A) Antitumor activity of Doxil in UM-SCC-22B tumor model. The mice were implanted subcutaneously with 
UM-SCC-22B cells expressing apoptosis-responsive cyclic firefly luciferase (cFluc). Two doses of Doxil (10 mg/kg on day 1, 
and day 3, i.v.) inhibited tumor growth. (B) In vivo bioluminescence imaging of tumors treated with Doxil (10 mg/kg) (top) or 
PBS (bottom) in the UM-SCC-22B tumor bearing mice. (C) Quantification of tumor BLI intensity (**, p < 0.01). Theranostics 2011, 1 
 
http://www.thno.org 
306 
 
Figure 2. (A) Representative decay-corrected whole-body coronal microPET images of mice bearing UM-SCC-22B tumors 
at 1 h after intravenous injection of 
18F-FDG (1.85 MBq/mouse) after Doxil or PBS treatment. The tumors are indicated by 
arrows. (B) Tumor uptake of 
18F-FDG quantified by ROI analysis (**, p < 0.01). 
 
Figure 3. (A) Representative decay-corrected whole-body coronal microPET images of mice bearing UM-SCC-22B tumors 
at 1 h after intravenous injection of 
18F-FLT (1.85 MBq/mouse) after Doxil or PBS treatment. The tumors are indicated by 
arrows. (B) Tumor uptake of 
18F-FLT quantified by ROI analysis (*, p < 0.05; **, p < 0.01). 
 
Figure 4. (A) Representative T1WI, T2WI and ADC maps of tumors treated with PBS, 1 dose or 2 doses of Doxil. (B) 
Tumor ADC quantified by region-of-interest (ROI) analysis (**, p < 0.01).  
T1WI            T2WI            ADC-map
PBS
1 Dose
2 Doses 
A B
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Histological analysis  
The  fluorescence  characteristics  of  doxorubicin 
can be used to monitor the localization of the drug 
within lipid bilayers and liposomal delivery systems 
and to assess interaction of the drug with DNA and 
other macromolecules [17]. Even at 48 hr after drug 
delivery, the presence of doxorubicin in the tumor cell 
nuclei could be clearly visualized by fluorescence mi-
croscopy. In addition, the drug showed homogenous 
distribution throughout the whole tumor (Figure 5A).  
 
Figure 5. Histologic analyis of tumor response to Doxil. Tumor samples treated with 2 doses of Doxil (10 mg/kg) or PBS 
were harvested for histological analysis. (A) Immunofluorescence staining of CD31and fluorescence from Doxorubicin in 
Doxil treated tumors. (B) Proliferation of UM-SCC-22B tumor cells after Doxil treatment as assessed by Ki-67 immuno-
fluorescence staining. (C) Ki67 positive cells were counted and the Ki-67 staining index (SI) was calculated by plotting Ki-67 
positive cell number against total cell number. A significant decrease in Ki67 SI was observed after Doxil treatment, 
compared to the control. Three samples were used from each group, and results were confirmed with a duplicate ex-
periment. (D) TUNEL staining of UM-SCC-22B tumor section after treatment with Doxil. Apoptotic nuclei are shown in 
green. Normal cell nuclei are shown in blue, stained by DAPI. (E) Apoptotic cells are counted by positive TUNEL staining, 
and apoptotic ratio is calculated by plotting TUNEL positive cell number against total cell number. **, p < 0.01. 
A
B DAPI                           Ki67                         Overlay
Doxil
PBS
DAPI                                 CD31                                 Doxil                               Overlay
C
DAPI                             TUNEL                            Overlay
Doxil
PBS
D E
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Examples of anti-Ki-67 stained sections for the 
controls and for the animals that received 2 doses of 
Doxil are shown in Figure 5B. In the control tumor 
sections,  a  relatively  high  percentage  of  cells  were 
stained positively for Ki-67, with a Ki-67 staining in-
dex (SI) of 56.9 ± 9.5 %. Significantly reduced cell pro-
liferation was observed in the Doxil treated mice with 
a Ki-67 SI of 5.4 ± 1.3 % (p < 0.001) (Figure 5C). 
A TUNEL assay is one of the traditional in vitro 
methods  to  characterize  cell  apoptosis,  and 
TUNEL-positive nuclei confirm DNA fragmentation. 
Compared  to  the  control  group,  the  group  that  re-
ceived  2  doses  of  Doxil  treatment  showed  signifi-
cantly more cell apoptosis, with an apoptotic index of 
51 ± 9% (P < 0.01, Figure 5D & E).  
 
Discussion 
In this study, we applied multiple imaging tech-
niques  to  monitor  tumor  responses  to  Doxil  treat-
ment--emphasizing  apoptosis-related  imaging,  be-
cause  doxorubicin  exerts  its  effects  by  inducing 
apoptosis  [18-19].  Traditionally,  apoptosis  can  be 
characterized  in  isolated  cells  by  in vitro  or  ex vivo 
methods, and these histological methods play an im-
portant role if tissue can be removed from the living 
system by biopsy. However, potential selection bias 
and lack of an ability to monitor the dynamic process 
of apoptosis can limit the usefulness of such studies 
[20].  Therefore,  there  has  been  growing  interest  in 
non-invasive,  functional  and  molecular  imaging 
techniques to observe apoptosis longitudinally [21].  
Although clinical use of optical imaging is lim-
ited by the poor penetration of light through tissues, it 
is useful for assessing superficial tumors, and a highly 
sensitive activatable probe or reporter gene approach 
could provide a robust platform for preclinical drug 
screening  and  therapy  monitoring  in  small  animal 
models [22]. To develop such a probe we began by 
genetically  engineered  UM-SCC-22B  cells  with  an 
endogenous apoptosis marker, cyclic firefly luciferase. 
The signal from this reporter gene is triggered after 
caspase-3  activation.  Living  cells  that  express  cyclic 
luciferase  can  be  used  for  quantitative  detection  of 
chemicals that induce or inhibit apoptosis [16]. After 
Doxil treatment, the BLI signal from the cyclic lucif-
erase  increased  significantly  in  a  dose  dependent 
manner. The results confirmed the previous finding 
that doxorubicin induces apoptosis via caspase-3 ac-
tivation [19]. More importantly, BLI imaging with the 
cyclic reporter gene is sensitive to apoptosis induced 
by Doxil as early as 24 hr after a single dose of Doxil, 
at which time no anatomical changes are yet apparent.  
Diffusion-weighted MRI (DW MRI) is a nonin-
vasive technique that probes the random microscopic 
motion of water molecules in vivo [23]. If tissue water 
can  diffuse  rapidly,  the  1H  magnetization  and  ob-
served  MRI  signal  will  not  refocus  as  much  in  the 
presence  of  a  bipolar  pulsed  field  gradient  [24].  By 
systematically increasing the strength of the gradient 
and  measuring  the  decrease  in  observed  1H  signal 
intensity, the apparent diffusion coefficient (ADC) can 
be determined. When b values are between 0 and 1000 
s/mm2, DWI detects mainly extracellular space water 
diffusion [25]. After one dose of Doxil treatment, BLI 
imaging  confirmed  tumor  cell  apoptosis  due  to  the 
induction of caspase protease. DWI MR detection of 
tumoral apoptosis relies on the observable shrinkage 
of the cell cytoplasm during tumor cell death, leading 
to decreased cell density and increased extracellular 
water space in the tumor, which occurs at a relatively 
late stage of the apoptosis process [26]. This is proba-
bly  why  no  ADC  value  change  was  observed  after 
only one dose of Doxil treatment.  
18F-FDG has been widely used both pre-clinically 
and clinically to monitor tumor glucose metabolism. 
Although  treatment  monitoring  with  18F-FDG  PET 
may have a significant impact on patient management 
in multiple clinical situations, published data on the 
accuracy  of  18F-FDG  PET  appear  controversial  [27]. 
We observed FDG signal changes after two doses of 
Doxil treatment, indicating the treatment reduced the 
tumor cell metabolism. 18F-FLT is the most extensively 
studied  probe  for  imaging  cellular  proliferation  in 
vivo. 18F-FLT PET is more specific than 18F-FDG PET in 
evaluating  tumor proliferation and tumor response, 
with  fewer  false  positive  findings  in  inflammatory 
lesions [28]. In our study, we did observe significantly 
decreased tumor uptake after 2 doses of Doxil treat-
ment, corroborating the change of Ki-67 index.  
Conclusions 
Apoptosis  is  a  very  complicated  and  dynamic 
process which is still not fully understood. Multiple 
imaging  techniques  may  provide  a  comprehensive 
description of apoptosis dominant tumor response to 
therapeutics such as Doxil. It is also essential to com-
bine  apoptosis  imaging  strategies  with  imaging  of 
other  biological  or  pathological  pathways,  such  as 
metabolism and proliferation, to improve pre-clinical 
decision  making  in  apoptosis-related  diseases  and 
interventions.  
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